Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

Journal of hepatology - 1 Dec 2014

Marcellin Patrick, Buti Maria, Krastev Zahari, de Man Robert A, Zeuzem Stefan, Lou Lillian, Gaggar Anuj, Flaherty John F, Massetto Benedetta, Lin Lanjia, Dinh Phillip, Subramanian G Mani, McHutchison John G, Flisiak Robert, Gurel Selim, Dusheiko Geoffrey M, Heathcote E Jenny

Abstract excerpt

BACKGROUND & AIMS: In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment. HBsAg kinetics in patients with and without HBsAg loss and predictors of HBsAg loss were evaluated. METHODS: HBsAg levels were quantified every 12 weeks. A multivariable regression analysis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Organophosphonates

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 25046847
DOI: 10.1016/j.jhep.2014.07.019
PMCID: PMC5976831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.PMID 25046847Read ↗

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.Semantic proximity Read ↗

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.Semantic proximity Read ↗

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.Semantic proximity Read ↗

Predictive Factors for HBsAg Loss in Chronic HBeAg-Negative Hepatitis B Virus Infection: Insights From a 5-Year French Cohort.Semantic proximity Read ↗

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.Semantic proximity Read ↗

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.Semantic proximity Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.Semantic proximity Read ↗

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BSemantic proximity Read ↗

Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarateSemantic proximity Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.